AI-generated antibodies tolerated by human immune cells
AI-generated antibodies have been tolerated by human immune cells, drug discovery company Latent Labs has announced.
The antibody designs, generated by Latent Labs’ AI platform, reportedly displayed drug-like properties, including low ex vivo immunogenicity.
Latent Labs hopes its platform, built on its Latent-X2 model, could significantly shorten the path from hit to clinical candidate. It is also hoped the model, which can generate antibodies and peptides for custom disease targets, could help reduce costs of wet labs approaches and provide a scientist-friendly workflow.
“Semiconductors, satellites and aircraft once required repeated build-test cycles, consuming years and billions of dollars,” said Simon Kohl, CEO and Founder of Latent Labs.
“Today they’re designed computationally before anything is fabricated.
“With Latent-X2, drug discovery can move towards that same step change – designing the right molecule from the start.”
The announcement comes as Stefan Oschmann, former CEO of Merck KGaA, has been appointed to Latent Labs’ strategic advisory board.
“The pharmaceutical industry has spent decades optimising around the limitations of iterative lab work,” Oschmann said.
“Latent Labs is doing something different – building the capability to design molecules that work from first principles. That shift, if it holds, changes the entire logic of drug discovery.”
Bruno Quinney, Content Team, DDW
